Psychiatric aspects of Parkinson's disease: An Update

Journal of Neurology

Volumn 251, Issue 7, 2004, Pages 795-804

  Schrag, Anette ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Dementia; Depression; Parkinson's disease; Psychosis; Treatment

Indexed keywords

AMANTADINE; AMITRIPTYLINE; ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLOZAPINE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; FLUVOXAMINE; LEVODOPA; METHYLPHENIDATE; MIRTAZAPINE; MOCLOBEMIDE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PRAMIPEXOLE; QUETIAPINE; REBOXETINE; RISPERIDONE; RIVASTIGMINE; ROPINIROLE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ANXIETY DISORDER; APATHY; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONFUSION; DELIRIUM; DELUSION; DEMENTIA; DEPRESSION; DISABILITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DREAM; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG UTILIZATION; DYSAUTONOMIA; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; LEUKOPENIA; MANIA; MENTAL DISEASE; MENTAL HEALTH; MOTOR DYSFUNCTION; PANIC; PARKINSON DISEASE; PATHOPHYSIOLOGY; PATIENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; SYMPTOM;

ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DEPRESSIVE DISORDER; DRUG INTERACTIONS; HUMANS; MOOD DISORDERS; PARKINSON DISEASE; PSYCHOTIC DISORDERS; SEROTONIN UPTAKE INHIBITORS;

EID: 3442876461     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, Tandberg E, Cummings JL (1999) Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 67:492-496
2. Aarsland D, Larsen JP, Cummins JL, Laake K (1999) Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 56:595-601
3. Aarsland D, Larsen JP, Tandberg E, Laake K (2000) Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 48:938-942
4. Aarsland D, Cummings JL, Larsen JP (2001) Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. Int J Geriatr Psychiatry 16:184-191
5. Aarsland D, Ballard C, Larsen JP, McKeith I (2001) A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 16:528-536
6. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60: 387-392
7. Aarsland D, Litvan I, Larsen JP (2001) Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson's disease. J Neuropsychiatry Clin Neurosci 13:42-49
8. Barrett K (1991) Treating organic abulia with bromocriptine and lisuride: four case studies. J Neurol Neurosurg Psychiatry 54:718-721
9. Bergman J, Lerner V (2002) Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 25:107-110
10. Bullock R, Cameron A (2002) Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin 18:258-264
11. Ceravolo R, Nuti A, Piccinni A, Dell'Agnello G, Bellini G, Gambaccini G, Dell'Osso L, Murri L, Bonuccelli U (2000) Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology 55:1216-1218
12. Chatterjee A, Fahn S (2002) Methylphenidate treats apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 14:461-462
13. Comella CL, Tanner CM, Ristanovic RK (1993) Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neurol 34:710-714
14. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL (2000) Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 11:58-65
15. Cubo E, Bernard B, Leurgans S, Raman R (2000) Cognitive and motor function in patients with Parkinson's disease with and without depression. Clin Neuropharmacol 23:331-334
16. Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy R, Dubois B (2002) Motivation, reward, and Parkinson's disease: influence of dopatherapy. Neuropsychologia 40:2257-2267
17. Dell'Agnello G, Ceravolo R, Nuti A, Bellini G, Piccinni A, D'Avino C, Dell'Osso L, Bonuccelli U (2001) SSRIs do not worsen Parkinsoris disease: evidence from an open-label, prospective study. Clin Neuropharmacol 24: 221-227
18. Deuschl G, Wenzelburger R, Kopper F, Volkmann J (2003) Deep brain stimulation of the subthalamic nucleus for Parkinson's disease: a therapy approaching evidence-based standards. J Neurol 250(Suppl 1):I43-I46
19. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ (2000) Brain serotonin IA receptors in Parkinson's disease with and without depression measured by positron emission tomography with 11C-WAY 10635. Mov Disord 15:213
20. de Smet Y, Ruberg M, Serdaru M, Dubois B, Lhermitte F, Agid Y (1982) Confusion, dementia and anticholinergics in Parkinson's disease. J Neurol Neurosurg Psychiatry 45:1161-1164
21. Dragasevic N, Potrebic A, Damjanovic A, Stefanova E, Kostic VS (2002) Therapeutic efficacy of bilateral prefrontal slow repetitive transcranial magnetic stimulation in depressed patients with Parkinson's disease: an open study. Mov Disord 17:528-532
22. Ellgring H, Seiler S, Perleth B, Frings W, Gasser T, Oertel W (1993) Psychosocial aspects of Parkinson's disease. Neurology 43(12 Suppl 6): S41-S44
23. Emre M (2003) What causes mental dysfunction in Parkinson's disease? Mov Disord 18(Suppl 6):S63-S71
24. Fenelon G, Mahieux F, Huon R, Ziegler M (2000) Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 123:733-745
25. Friedman JH, Feinberg SS, Feldman RG (1985) A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal. JAMA 254:2792-2795
26. Giladi N, Treves TA, Paleacu D, Shabtai H, Orlov Y, Kandinov B, Simon ES, Korczyn AD (2000) Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease. J Neural Transm 107:59-71
27. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ (2000) Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68:423-428
28. Global Parkinson's Disease Survey Steering Committee (2002) Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 17:60-67
29. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ (2000) Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 55:789-794
30. Goetz CG, Leurgans S, Pappert EJ, Raman R, Stemer AB (2001) Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology 57:2078-2082
31. Goetz CG, Stebbins GT (1995) Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 45:669-671
32. Gomez-Tortosa E, Newell K, Irizarry MC, Albert M, Growdon JH, Hyman BT (1999) Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology 53:1284-1291
33. Gotham AM, Brown RG, Marsden CD (1986) Depression in Parkinson's disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 49:381-389
34. Hantz P, Caradoc-Davies G, Caradoc-Davies T, Weatherall M, Dixon G (1994) Depression in Parkinson's disease. Am J Psychiatry 151:1010-1014
35. Harding AJ, Halliday GM (2001) Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol (Berl) 102:355-363
36. Houeto JL, Mesnage V, Mallet L, Pillon B, Gargiulo M, du Moncel ST, Bonnet AM, Pidoux B, Dormont D, Cornu P, Agid Y (2002) Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 72:701-707
37. Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Mindham RH, Spokes EG (2000) A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 54:1596-1602
38. Higginson CI, Fields JA, Troster AI (2001) Which symptoms of anxiety diminish after surgical interventions for Parkinson disease? Neuropsychiatry Neuropsychol Behav Neurol 14: 117-121
39. Holroyd S, Currie L, Wooten GF (2001) Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 70: 734-738
40. Huckvale C, Richardson AM, Mann DM, Pickering-Brown SM (2003) Debrisoquine hydroxylase gene polymorphism (CYP2D6*4) in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 74:135-136
41. Fukuda M, Kameyama S, Yoshino M, Tanaka R, Narabayashi H (2000) Neuropsychological outcome following pallidotomy and thalamotomy for Parkinson's disease. Stereotact Funct Neurosurg 74:11-20
42. Hurtig HI, Trojanowski JQ, Calvin J, Ewbank D, Schmidt ML, Lee VM, Clark CM, Glosser G, Stern MB, Gollomp SM, Arnold SE (2000) Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 54:1916-1921
43. Hutchinson M, Fazzini E (1996) Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 61:324-325
44. Inzelberg R, Chapman J, Treves TA, Asherov A, Kipervasser S, Hilkewicz O, Verchovsky R, Klimowitzky S, Korczyn AD (1998) Apolipoprotein E4 in Parkinson disease and dementia: new data and meta-analysis of published studies. Alzheimer Dis Assoc Disord 12:45-48
45. Jellinger KA (2000) Morphological substrates of mental dysfunction in Lewy body disease: an update. J Neural Transm 59(Suppl):185-212
46. Karlsen KH, Larsen JP, Tandberg E, Maeland JG (1999) Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 66:431-435
47. Korczyn AD (2001) Dementia in Parkinson's disease. J Neurol 248(Suppl 3):III1-III4
48. Kulisevsky J, Berthier ML, Gironell A, Pascual-Sedano B, Molet J, Pares P (2002) Mania following deep brain stimulation for Parkinson's disease. Neurology 59:1421-1424
49. Leentjens AF, Lousberg R, Verhey FR (2002) Markers for depression in Parkinson's disease. Acta Psychiatr Scand 106:196-201
50. Lees AJ, Smith E (1983) Cognitive deficits in the early stages of Parkinson's disease. Brain 106:257-270
51. Lemke MR (2002) Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 63:300-304
52. Levy G, Schupf N, Tang MX, Cote LJ, Louis ED, Mejia H, Stern Y, Marder K (2002a) Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol 51: 722-729
53. Levy G, Tang MX, Louis ED, Cote LJ, Alfaro B, Mejia H, Stern Y, Marder K (2002b) The association of incident dementia with mortality in PD. Neurology 59:1708-1713
54. Louis ED, Marder K, Cote L, Tang M, Mayeux R (1997) Mortality from Parkinson disease. Arch Neurol 54: 260-264
55. Manford M, Andermann F (1998) Complex visual hallucinations. Clinical and neurobiological insights. Brain 121:1819-1840
56. Maricle RA, Nutt JG, Valentine RJ, Carter JH (1995) Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study. Neurology 45:1757-1760
57. Mayberg HS, Starkstein SE, Sadzot B, Preziosi T, Andrezejewski PL, Dannals RF, Wagner HN Jr, Robinson RG (1990) Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann Neurol 28:57-64
58. Mayeux R, Stern Y, Rosen J, Leventhal J (1981) Depression, intellectual impairment, and Parkinson disease. Neurology 31:645-650
59. Mayeux R, Chen J, Mirabello E, Marder K, Bell K, Dooneief G, Cote L, Stern Y (1990) An estimate of the incidence of dementia in idiopathic Parkinson's disease. Neurology 40:1513-1517
60. Mayeux R (1992) The mental status in Parkinson's disease. In: Koller WC (ed). Handbook of Parkinson's disease. Second edition. Marcel Dekker Inc., pp 159-184
61. Mayeux R (1990) The "serotonin hypothesis" for depression in Parkinson's disease. Adv Neurol 53:163-166
62. McKeith IG, Grace JB, Walker Z, Byrne EJ, Wilkinson D, Stevens T, Perry EK (2000) Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry 15:387-392
63. McKeith IG, Galasko D, Kosaka K, et al. (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47: 1113-1124
64. Melamed E, Friedberg G, Zoldan J (1999) Psychosis: impact on the patient and family. Neurology 52(7 Suppl 3):S14-S16
65. Merello M, Starkstein S, Nouzeilles MI, Kuzis G, Leiguarda R (2001) Bilateral pallidotomy for treatment of Parkinson's disease induced corticobulbar syndrome and psychic akinesia avoidable by globus pallidus lesion combined with contralateral stimulation. J Neurol Neurosurg Psychiatry 71: 611-614
66. Moellentine C, Rummans T, Ahlskog JE, Harmsen WS, Suman VJ, O'Connor MK, Black JL, Pileggi T (1998) Effectiveness of ECT in patients with parkinsonism. J Neuropsychiatry Clin Neurosci 10:187-193
67. rd, Klawans HL (1978) Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 135:669-675
68. Movement Disorders Task Force (2002) Treatment of depression in idiopathic Parkinson's disease. Mov Disord 17:112-119
69. Movement Disorders Task Force (2002) Drugs to treat dementia and psychosis. Mov Disord 17:120-127
70. Naimark D, Jackson E, Rockwell E, Jeste DV (1996) Psychotic symptoms in Parkinson's disease patients with dementia. J Am Geriatr Soc 44:296-299
71. Nausieda PA, Glantz R, Weber S, Baum R, Klawans HL (1984) Psychiatric complications of levodopa therapy of Parkinson's disease. Adv Neurol 40: 271-277
72. Nilsson FM, Kessing LV, Sorensen TM, Andersen PK, Bolwig TG (2002) Major depressive disorder in Parkinson's disease: a register-based study. Acta Psychiatr Scand 106:202-211
73. Nissenbaum H, Quinn NP, Brown RG, Toone B, Gotham AM, Marsden CD (1987) Mood swings associated with the 'on-off' phenomenon in Parkinson's disease. Psychol Med 17:899-904
74. Oertel WH, Hoglinger GU, Caraceni T, Girotti F, Eichhorn T, Spottke AE, Krieg JC, Poewe W (2001) Depression in Parkinson's disease. An update. Adv Neurol 86:373-383
75. Perry EK, Irving D, Kerwin JM, McKeith IG, Thompson P, Collerton D, Fairbairn AF, Ince PG, Morris CM, Cheng AV, et al. (1993) Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 7:69-67
76. Rampello L, Chiechio S, Raffaele R, Vecchio I, Nicoletti F (2002) The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa. Clin Neuropharmacol 25:21-24
77. Raudino F (2001) Non motor off in Parkinson's disease. Acta Neurol Scand 104:312-315
78. Reading PJ, Luce AK, McKeith IG (2002) Rivastigmine in the treatment of parkinsonian hallucianosis. Neurology 58(Suppl 7):A380
79. Ring HA, Bench CJ, Trimble MR, Brooks DJ, Frackowiak RS, Dolan RJ (1994) Depression in Parkinson's disease. A positron emission study. Br J Psychiatry 165:333-339
80. Romito LM, Raja M, Daniele A, Contarino MF, Bentivoglio AR, Barbier A, Scerrati M, Albanese A (2002) Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease. Mov Disord 17: 1371-1374
81. Schrag A, Ben-Shlomo Y, Quinn N (2002) How common are complications of Parkinson's disease? J Neurol 249:419-423
82. Schrag A, Jahanshahi M, Quinn N (2000) What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 69:308-312
83. Schrag A, Jahanshahi M, Quinn NP (2001) What contributes to depression in Parkinson's disease? Psychol Med 31:65-73
84. Scott RB, Harrison J, Boulton C, Wilson J, Gregory R, Parkin S, Bain PG, Joint C, Stein J, Aziz TZ (2002) Global attentional-executive sequelae following surgical lesions to globus pallidus interna. Brain 125:562-574
85. Shiba M, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA (2000) Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 15:669-677
86. Shulman LM, Taback RL, Bean J, Weiner WJ (2001) Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov Disord 16:507-510
87. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG (1992) Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 4:134-139
88. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG (1990) Depression in Parkinson's disease. J Nerv Ment Dis 178:27-31
89. Steur EN, Ballering LA (1997) Moclobemide and selegeline in the treatment of depression in Parkinson's disease. J Neurol Neurosurg Psychiatry 63:547
90. Straits-Troster K, Fields JA, Wilkinson SB, Pahwa R, Lyons KE, Koller WC, Troster AI (2000) Health-related quality of life in Parkinson's disease after pallidotomy and deep brain stimulation. Brain Cogn 42:399-416
91. Tandberg E, Larsen JP, Aarsland D, Cummings JL (1996) The occurrence of depression in Parkinson's disease. A community-based study. Arch Neurol 53:175-179
92. Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani CB, Pezzoli G (2000) Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov Disord 15:986-989
93. The Parkinson Study Group (1999) Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 340: 757-763
94. Vijayaraghavan L, Krishnamoorthy ES, Brown RG, Trimble MR (2002) Abulia: a delphi survey of British neurologists and psychiatrists. Mov Disord 17: 1052-1057
95. Walsh K, Bennett G (2001) Parkinson's disease and anxiety. Postgrad Med J 77:89-93
96. Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, Poncet M, Cherif AA (2002) Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 59:408-413
97. Wolters EC (1999) Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment. Neurology 52(7 Suppl 3):S10-S13